Table 1A.

Continued.

a The percent responses are noted in parentheses after the questions. Percentages may add up to >100% because some responders may have indicated more than one option. CAD, coronary artery disease; PSA, prostate-specific antigen.
11. How often would such screening typically take place?
    a. Annually (79%)
    b. Biannually (12%)
    c. Other protocol (7%)
12. What is the preferred modality for screening for CAD in your program?
    a. Coronary angiography (15%)
    b. Chemical stress nuclear perfusion study (41%)
    c. Chemical stress echocardiography (30%)
    d. Exercise stress with thallium (31%)
    e. Exercise stress only (7%)
    f. Other (7%)
13. Does your kidney transplant program have a designated cardiologist or group of cardiologists?
    a. Yes (56%)
    b. No (44%)
14. Are follow-up requirements more intensive for patients awaiting pancreas transplants?
    a. Yes (49%)
    b. No (51%)
15. Standard cancer prevention screening recommendations are available for the general population for breast cancer, cervical cancer, and colon cancer. Does your program insist that wait-listed patients abide by these recommendations?
    a. Yes (69%)
    b. No (11%)
    c. Decision is left to the dialysis nephrologist (20%)
16. Other than blood testing for the purpose of crossmatching, are certain blood tests required on a regular basis by your program? Please check relevant tests.
    a. Hepatitis serologic tests (80%)
    b. Other infectious serologic tests (52%)
    c. PSA in older male patients (79%)
    d. Other (9%)
17. How often are patients called in for transplants at your center and then sent home because of unanticipated medical problems (excluding positive crossmatch)?
    a. Rare occurrence (<2%) (57%)
    b. 2 to 5% (28%)
    c. 5 to 10% (12%)
    d. 10 to 20% (3%)
    e. >20% (1%)
18. How often are listed patients taken off the list or put “on hold” because of intercurrent medical or psychosocial problems?
    a. Rare occurrence (<2%) (11%)
    b. 2 to 5% (33%)
    c. 5 to 10% (35%)
    d. 10 to 20% (18%)
    e. >20% (4%)
19. With respect to marginal cadaveric donors,
    a. Do you maintain a separate transplant list for candidates for marginal kidneys? (12%)
    b. Do you inform patients at the time of transplant that a donor kidney may have unfavorable features that could affect short- or long-term function? (81%)
    c. Do you ask patients whether they would accept a marginal kidney at the time they are listed? (40%)
    d. Is the dialysis nephrologist consulted regarding the marginal features of a cadaveric donor? (60%)
20. Any other comments regarding the management of the waiting list or the questions in this survey?